VismoHisto
Published: 5 December 2019| Version 1 | DOI: 10.17632/wsdgt4cf8y.1
Contributors:
, Melinda Chu, , , , , , , , , Description
Supporting data for JAAD manuscript entitled: Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular and superficial) of high risk and/or locally advanced basal cell carcinoma, in an open label prospective case series clinical trial.
Files
Institutions
Saint Louis University School of Medicine
Categories
Oncology, Pathology, Basal Cell Carcinoma, Vismodegib, Histopathology, Non-Melanoma Skin Cancer, Hedgehog